Navigation Links
Mom's Low Cholesterol Tied to Preemie Births
Date:10/1/2007

Nutritional deficiencies and genetics may be to blame, researchers suggest,,

MONDAY, Oct. 1 (HealthDay News) -- While lower cholesterol is generally considered a good thing, new research suggests that very low cholesterol levels in pregnant women may harm the health of the fetus.

Expectant mothers whose total cholesterol levels were under 159 milligrams per deciliter (mg/dL) gave birth -- on average -- to babies weighing about one-third of a pound less than babies born to mothers whose cholesterol levels exceeded 159 mg/dL, the researchers found.

Additionally, 12.7 percent of white women with low cholesterol levels gave birth prematurely, compared to just five percent of those with higher cholesterol levels. No such association was found in black women, however.

"To our surprise, we found that white women with very low cholesterol also have a significant risk of having babies born prematurely," said Dr. Max Muenke, chief of medical genetics at the U.S. National Human Genome Research Institute in Bethesda, Md.

Results of the study are in the October issue of Pediatrics.

"At this point, it's not even clear if it's the low cholesterol itself, or another lipid," he said, adding that more research is needed to confirm these findings.

"This study intuitively makes some sense," said Dr. Robert Welch, chair and program director for obstetrics and gynecology at St. John Health's Providence Hospital in Southfield, Mich. "Cholesterol is a building block for membranes, hormones and proteins, so it makes sense that if you have low cholesterol, your baby won't have the substrate it needs to grow."

Each year, more than half a million babies are born prematurely in the United States, according to the March of Dimes. Medical advances have brought down the incidence rates for many diseases and conditions, but that's not been the case with premature or low birth weight babies.'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Changes in cabin pressure pose risks for moms-to-be
2. Phone Calls Lend Vital Support to Moms of Mentally Ill Children
3. Basic Instinct drives wannabe moms
4. Still Births: Three Times Higher Risk for Older Moms–to–e
5. Ire of Irish Moms pained over maternity services in Ireland.
6. Moms to be, beware of meth - It can hamper growth and development in your babies
7. Underweight Moms: Weighed Down by the Risk of Miscarriages
8. Mental Disorders Strike First Time Moms More
9. Special Delivery Unit for Pregnant Moms With Birth Defects in Fetus
10. New Moms Must Not Skip Meals
11. Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
... they use plates and cereal bowls with markers for...e study was undertaken by researchers at the Unive... Pedersen, F.R.C.P.C. They team conducted a six-m...f commercially available portion control plates an...
...are famous for sloppy scribbling and handwritten ...rs each year. Electronics to the rescue: U.S. hos...er entry systems saw a 66 percent drop in prescrip...d transcription errors are responsible for as much...
... fruit fly, Drosophila melanogaster has been ident...arch in Biomedicine (IRB Barcelona). The researc...nerate the same signal by different pathways and t...ether to send the signal to the target cell. In th...
...ted that wind blown dust from drought-stricken and... duration of mountain snow cover hundreds of miles.... The study found that seasonal snow coverage in ...he San Juan Mountains of southwestern Colorado dis...
Other Medicine News:Health News:Using Portion-control Dishes can Help Obese Diabetics Lose Weight 2Health News:Computerized Doctors Order Reduce Prescription Errors 2Health News:Computerized Doctors Order Reduce Prescription Errors 3Health News:A New Signaling Mechanism in Drosophila 2Health News:Desert Droughts Shorten Mountain Snow Cover, Reveals Study 2
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Factor key to severity of community associated methicillin resistant staph infections identified 6042 1Factor key to severity of community associated methicillin resistant staph infections identified 6042 2Factor key to severity of community associated methicillin resistant staph infections identified 6042 3Life threatening gene defect located by UT Houston researchers 1176 1Life threatening gene defect located by UT Houston researchers 1176 2Life threatening gene defect located by UT Houston researchers 1176 3Life threatening gene defect located by UT Houston researchers 1176 4Research suggests targeted treatment strategies for lupus 6037 1Research suggests targeted treatment strategies for lupus 6037 2Human clones 3A New U N analysis lays out worlds choices 1174 1Human clones 3A New U N analysis lays out worlds choices 1174 2Human clones 3A New U N analysis lays out worlds choices 1174 3Human clones 3A New U N analysis lays out worlds choices 1174 4
...ate breaking data,presented at the American Diabet...ns showed that, when used investigationally as,ini...tion with,metformin provided significant glycemic ...54 weeks in patients with type 2,diabetes. Additio...d also showed that JANUVIA significantly improved ...
...cant Clinical Results for,SB-509 in Development fo...22, 2007 /PRNewswire-FirstCall/ -- Sangamo,BioScie...ouraging,Phase 1 clinical data from its ZFP Therap...of the American Diabetes Association,(ADA). As dis...,Neurologic Exam and Nerve Conduction Velocities i...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: